|
Originally published In Press as doi:10.1074/jbc.M203374200 on May 1, 2002
J. Biol. Chem., Vol. 277, Issue 29, 26036-26045, July 19, 2002
A Highly Active Homeobox Gene Promoter Regulated by Ets and Sp1
Family Members in Normal Granulosa Cells and Diverse Tumor Cell
Types*
Manjeet K.
Rao,
Sourindra
Maiti,
Honnavara N.
Ananthaswamy, and
Miles F.
Wilkinson
From the Department of Immunology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Received for publication, April 8, 2002, and in revised form, April 22, 2002
 |
ABSTRACT |
One mechanism by which normal cells become
converted to tumor cells involves the aberrant transcriptional
activation of genes that are normally silent. We characterize a
promoter that normally exhibits highly tissue- and stage-specific
expression but displays ubiquitous expression when cells become
immortalized or malignant, regardless of their lineage or tissue
origin. This promoter normally drives the expression of the
Pem homeobox gene in specific cell types in ovary and
placenta but is aberrantly expressed in lymphomas, neuroblastomas,
retinoblastomas, carcinomas, and sarcomas. By deletion analysis we
identified a region between nucleotides 80 and 104 that was
absolutely critical for the expression from this distal Pem
promoter (Pem Pd). Site-specific mutagenesis and transfection studies revealed that this region contains two consensus Ets sites and a single Sp1 site that were necessary for Pem
Pd expression. Gel shift analysis showed that Ets and Sp1 family members bound to these sites. Transfection studies demonstrated that
the Ets family members Elf1 and Gabp and the Sp1 family members Sp1 and Sp3 transactivated the Pem Pd. Surprisingly, we
found that Sp3 was a more potent activator of the Pem Pd
than was Sp1; this is unusual, because Sp3 is either a weak activator
or a repressor of most other promoters. Activation by either Elf1 or
Gabp required an intact Sp1 family member binding site, suggesting that
Ets and Sp1 family members cooperate to activate Pem Pd
transcription. Expression from the Pem Pd (either
transiently transfected or endogenous) depended on the Ras
pathway, which could explain both its Ets- and
Sp1-dependent expression in normal cells and its aberrant
expression in tumor cells, in which ras protooncogenes are
frequently mutated. We suggest that the Pem Pd may be a
useful model system to understand the molecular mechanism by which a tissue-specific promoter can be corrupted in tumor cells.
 |
INTRODUCTION |
The malignant and metastatic characteristics of cancer cells
derive in part from the deregulation of genes whose normal role is to
control the division, differentiation, and migration of embryonic cells
during development (1). One important class of genes that regulates
both developmental and tumorigenic events is the homeobox gene family
(2, 3). This gene family encodes a large group of transcription factors
that each contain a 60-amino acid DNA-binding motif termed a homeodomain.
Although much is known about the function of homeodomain transcription
factors, little is known about the regulation of the genes that encode
them, particularly in response to signals in tumor cells. One homeobox
gene of interest in this regard is Pem, which we originally
cloned by subtraction hybridization from a T cell lymphoma clone (4,
5). Pem is the founding member of the recently defined
PEPP homeobox subfamily, a small group of homeobox genes on
the X chromosome that are all normally expressed in reproductive
tissues (6-8). Pem is expressed in parietal and visceral endodermal
cells, where it appears to regulate the development of cells that
eventually form portions of the placenta (5, 9, 10). In neonatal and
adult mice and rats, Pem is specifically expressed in ovary, testis,
and epididymis (10-12). In the ovary, Pem expression is restricted to
granulosa cells of preovulatory follicles. In the testis, Pem is
specifically expressed in Sertoli cells at stages VI-VIII of the
seminiferous epithelial cycle. In striking contrast to its tissue- and
stage-specific expression in normal tissues, Pem is aberrantly
expressed in a wide range of tumor cell types regardless of their
origin (5). It is not known whether the ubiquitous expression of Pem in
tumors reflects a causal role for Pem in promoting tumor cell growth
and metastasis or whether instead Pem expression is a consequence of
immortalization and malignant conversion. In support of the former, it
was shown recently that Pem physically interacts with the tumor
suppressor protein menin (13) and is a potent tumor antigen (14).
We showed previously (15) that Pem transcripts
are derived from two promoters that are independently regulated in a
tissue-specific manner. The proximal promoter (Pem Pp) is
expressed exclusively in male reproductive tissues, whereas the distal
promoter (Pem Pd) is preferentially transcribed in the
female reproductive tissues ovary and placenta (7, 15). In the present
investigation, we determined which promoter is responsible for the
ubiquitous expression of Pem in tumor cells. We found that
the Pem Pd was responsible for this aberrant expression. We
then defined the cis elements upstream of the Pem
Pd transcription start site that were necessary and sufficient for
expression in both tumor cells and normal granulosa cells. We
identified specific Ets and Sp1 transcription factor family members
that bound to these cis elements and controlled the
expression of Pem in a ras-dependent
manner. Our data suggest that the Pem Pd is normally a
tissue-specific promoter that is aberrantly expressed in diverse tumor
cell types because it is activated by ubiquitously expressed
transcription factors that are regulated in normal cells but
constitutively activated in tumor cells.
 |
EXPERIMENTAL PROCEDURES |
Cells, Chemicals, and Biochemicals--
The SL12.1,
SL12.3, SL12.4, N4TG1, M12, Ras/RAT-1, PS-1, S194/5, and 10T1/2 cell
lines were maintained in tissue culture plates containing Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum and
50 mg of both penicillin and streptomycin per ml. Drosophila
melanogaster SL2 Schneider cells were kindly provided by Dr. Mitzi
Kuroda (Baylor College of Medicine, Houston, TX) and were maintained in
tissue culture flasks containing Schneider's D. melanogaster medium (Invitrogen) supplemented with 10% fetal bovine serum and 50 mg of both penicillin and streptomycin per ml. All
cell culture reagents were obtained from Invitrogen. Antibodies for Sp1
(Sp1 SC-420), Sp3 (Sp3 D-20), and Elf1 (C-20) were obtained from Santa
Cruz Biotechnology. Rabbit polyclonal antibodies, directed against
recombinant GABP and GABP 1 (16), were gifts from Dr. Thomas Brown (Pfizer, Groton, CT).
Granulosa Cell Culture--
Immature female rats (55-60 g, 23 days old) were injected with 1.5 mg of 17- -estradiol per day and
then kept for 3 days before granulosa cells were harvested. The rats
were treated in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. All protocols were approved
by the Institutional Committee on Animal Care of M. D. Anderson
Cancer Center. Ovarian granulosa cells were isolated as described
previously (17). Briefly, the ovaries were punctured multiple times
with a 22-gauge needle to isolate granulosa cells. The granulosa cells were pooled and treated with 20 µg of trypsin per ml for 1 min, and
then 300 µg of soybean trypsin inhibitor per ml and 160 µg of DNase
I per ml were added to remove necrotic cells. The cells were washed
twice and cultured in Dulbecco's modified Eagle's medium:F-12 medium
at 37 °C in 95% air and 5% CO2 for 16 h.
Plasmids--
A 1.3-kb SpeI-SalI rat
genomic Pem fragment containing exon 1 and upstream
sequences (15) was cloned into the eukaryotic expression vector
pRL-Null (Promega) to generate the 304 construct (Pem-128). This construct was then used as a PCR template to
generate deletion constructs 112 (Pem-147),
104 (Pem-170), 94 (Pem-167), and
73 (Pem-148), which were each made by using a
T3 polymerase antisense oligonucleotide (oligo) in combination
with the sense oligos MDA-298, MDA-396, MDA-392, and MDA-319,
respectively (Table I). All of
these sense primers contained an NdeI site except for the
primer used to generate Pem-148, which contained an
XhoI site instead. Substitution mutations were generated
with the QuickChange site-directed mutagenesis kit (Stratagene Inc.)
according to the manufacturer's instructions and then confirmed by DNA
sequencing. The site-specific mutagenized constructs 112/S1
(Pem-171), 112/E1 (Pem-172), and 112/E2
(Pem-175) were made by using the sense oligos MDA-397,
MDA-399, and MDA-419, in combination with the antisense oligos MDA-398,
MDA-400, and MDA-420, respectively. To generate the 81 to
104/ c-fos construct (Pem-179), a single copy
of sequences nt1 104 to
81 was cloned into the SalI-HindIII site of the
plasmid 56FosdE-luciferase (kindly provided by Craig A. Hauser,
Burnham Institute, La Jolla, CA), which contains a minimal
c-fos promoter. The D. melanogaster expression
plasmids pPac-Sp1 and pPac-Sp3 were kindly
provided by Guntram Suske (Institut for Molekularbiologie and
Tumorfurchung, Marburg, Germany). The D. melanogaster
expression plasmids pPac-Elf1 and pPac-Uo were a gift
from Philip A. Marsden (University of Toronto, Toronto, Canada). The
D. melanogaster expression plasmids pPac-Gabp and were kindly provided by Thomas Brown (Pfizer).
pCMV-DNSp3, which encodes the dominant negative
(DN) form of Sp3 in pCDNA3.1/His C, was generously provided by
Yoshihiro Sowa and Toshiyuki Sakai (Kyoto Prefectural University of
Medicine, Kyoto, Japan). DN-Gabp and expression
plasmids were provided by Seroz Thierry (Neurobiologie Moleculaire,
Institut Pasteur, France). The DN-ras (17N) and activated
Ha-ras (61L) expression plasmids were kindly provided by
Craig A. Hauser (Burnham Institute, La Jolla, CA).
Transient Transfection Assays--
For transfections, DNA
concentrations were independently determined by using a fluorometer and
analytical gel electrophoresis. Before transfection, all mammalian cell
lines were replated in 6-well plates at a density of ~106
cells per well in 0.8 ml of serum-free medium. Plasmid DNA was suspended in 100 µl of serum-free medium, mixed with 100 µl of serum-free medium premixed with 15 µl of LipofectAMINE (Invitrogen), and then incubated for 40 min at room temperature. The DNA-lipid complex was then added to the wells and incubated at 37 °C in a
CO2 incubator for 12-14 h. The cells were then replenished
with fresh medium containing serum and incubated for 48 h. Stably
transfected SL12.4 and 10T1/2 stable cell lines were generated by
providing 2 mg/ml G418 every other day until only antibiotic-resistant
cells remained alive (2-3 weeks).
D. melanogaster Schneider cells and primary ovarian
granulosa cells were transfected by using the calcium phosphate method (18). Briefly, plasmid DNA diluted in 2× HBS buffer (280 mM NaCl, 1.5 mM
Na2HPO4, and 50 mM Hepes (pH 7.2))
was precipitated by dropwise addition of 250 mM
CaCl2. After incubation for 30 min, 300 µl of the DNA
precipitate was added dropwise to each well, and then the cells were
incubated for 6-8 h at 26 °C (for the Schneider cells) or at
37 °C (for the granulosa cells). The incubation medium was then
carefully aspirated and replaced with fresh media, and then the
Schneider and granulosa cells were incubated for 48 and 6 h, respectively.
Cell lysates for luciferase assay were prepared by centrifuging the
cells at 1000 rpm (750 relative centrifugal force) for 2 min,
and then 1× lysis buffer (Promega) was added to the cell pellet.
Luciferase activity was measured by the dual luciferase reporter assay
system (Promega) according to the manufacturer's instructions. For all
transient transfection experiments, Renilla luciferase
activity from the Pem Pd was normalized relative to firefly
luciferase activity expressed from a thymidine kinase promoter-driven
construct (pGL2TK). Expression from plasmids containing Pem
sequences was compared with the empty control vectors pRL-Null, pPac,
or c-fos.
RNA Isolation, Northern Blot, and Ribonuclease Protection
Analysis (RPA)--
Total cellular RNA was isolated as described
previously by guanidinium isothiocyanate lysis and centrifugation over
a 5.7 M CsCl cushion (4). The Pem cDNA probe
used for Northern blot analysis was prepared as described previously
(5). A cyclophilin cDNA probe (19) was used as a loading control.
RNA was analyzed by RPA, performed as described previously (11). The
[32P]UTP-labeled mouse Pem RPA probe was
prepared by in vitro transcription, as described
previously (Pem probe E) (15). The -actin RPA probe was
prepared in the same manner; it contained nt 135-169 of human
-actin exon 3 (GenBankTM accession number X00351). A set
of RNA size markers generated from the century ladder template (Ambion,
Inc.) was included in all gels.
Nuclear Extract Preparation and Electrophoretic Mobility Shift
Assay (EMSA)--
Crude nuclear extracts used for EMSAs were prepared
as follows. SL12.4 cells (~107) were collected by
centrifuging the cells at 700 rpm (~400 relative centrifugal
force) for 3 min. The cells were then washed with ice-cold Tris-saline,
resuspended in 400 µl of hypotonic buffer A (10 mM Hepes
(pH 7.9), 10 mM KCl, 0.1 mM EDTA (pH 8.0), 0.1 mM EGTA (pH 8.0), 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride), and incubated on ice for
15 min. The cells were then centrifuged at 2000 rpm (3100 relative centrifugal force) for 30 s and resuspended in 400 µl of buffer B (buffer A plus 0.15% Nonidet P-40) on ice for 15 min.
Nuclear proteins were extracted in 100 µl of hypertonic buffer C (20 mM Hepes (pH 7.9), 400 mM NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0), 1 mM dithiothreitol, and 1 mM
phenylmethylsulfonyl fluoride) at 4 °C on a rocking platform.
EMSAs were performed by using a 32P-labeled blunt-end
double-stranded probe generated by annealing two complementary
oligonucleotides (oligos) (MDA-473 and MDA-474). The probe (5 × 104 cpm) was incubated for 30 min at room temperature in 20 µl of binding buffer (10 mM Tris (pH 7.9), 50 mM NaCl, 1 mM dithiothreitol, 1 mM
EDTA, 5% glycerol, and 1 µg of poly(dI·dC)) containing 1 µg of nuclear extract. For antibody supershift and blocking assays the reaction mixture was preincubated with monoclonal antibodies or
polyclonal antisera (2 µg) at room temperature for 20 min before addition of the 5' 32P-labeled blunt-ended double-stranded
oligonucleotide. The DNA-protein complexes were resolved on 4.5-5%
non-denaturing polyacrylamide gels at 150 V for 3-4 h at 4 °C.
 |
RESULTS |
Diverse Tumor Cells Express Pem Transcripts from the Pem
Pd--
We showed previously (5) that despite its cell type-specific
expression in normal cells, Pem is ubiquitously expressed in
a variety of tumors cell lines regardless of their lineage. Here we
determined whether Pem is expressed in tumor cells from its
distal promoter (Pem Pd) or its proximal promoter
(Pem Pp). We investigated this issue in six tumor
cell lines derived from different tissues and cell lineages, all of
which expressed Pem mRNA, as assessed by Northern blot
analysis (Fig. 1A). To
determine promoter usage, RPA was performed with a probe that
distinguishes between Pem Pd- and Pem Pp-derived
transcripts (15). As shown in Fig. 1B, all cell lines
protected a band of ~80 nt that corresponded to the Pem Pd
transcript. In contrast, none of the cell lines expressed the Pem
Pp transcript, which is normally expressed in testes (Fig.
1B).

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 1.
The Pem Pd is
transcriptionally active in tumor cell lines. A,
Northern blot analysis of total cellular RNA (10 µg) isolated from
the following tumor cell lines: SL12.4 (T cell lymphoma), N4TG1
(neuroblastoma), M12 (B cell myeloma), PS-1 (transformed prostate
smooth muscle), S194/5 (B cell lymphoma), and Ras/RAT-1
(ras-transformed fibroblast). Similar loading and transfer of RNA were
verified by hybridization with a probe for cyclophilin
(cyclo). B, RPA of total cellular RNA (10 µg)
from testes and the cell lines shown were annealed with the
Pem and -actin probes. The length of the probe protected
was ~80 and ~140 nt for Pem Pd and Pp
mRNA, respectively, and ~40 nt for -actin mRNA.
|
|
A 32-nt Element Is Necessary and Sufficient for Pem Pd
Transcription--
We next determined the sequences important for
Pem Pd transcription. Promoter activity was assessed by
measuring luciferase levels in transiently transfected SL12.4 T
lymphoma cells. We first tested a construct containing 304 nt of
sequence upstream of the exon 1-intron 1 junction. As shown in Fig.
2A, this 304 construct
expressed high levels of luciferase activity (90-110-fold more than
empty vector), indicating that it contained sequences sufficient for
high level Pem Pd transcription.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Ets and Sp1 consensus sites are critical for
Pem Pd transcriptional activity. A-C,
the Pem gene constructs indicated were transiently
transfected (1 µg) into SL12.4 cells, and then luciferase
(luc) activity was measured. The values shown are
Renilla luciferase activity expressed from the
Pem constructs, normalized against firefly luciferase
activity from the pGL2TK internal control vector (±S.E.). A
shows expression from constructs containing the deletions indicated;
the numbers refer to the nts upstream of the exon 1-intron 1 junction
(the 1st black box is exon 1). Shown are the average values
(relative to luciferase expression from the 304 construct, which was
arbitrarily given a value of 100) from four independent transfection
experiments performed in triplicate. B shows the two
putative Ets family protein-binding sites (E1 and
E2) and the putative Sp1 family protein-binding site
(S1) that when mutated (indicated by lowercase
letters) abrogate Pem Pd transcription. Shown are the
average values (relative to luciferase expression from the 112
construct, which was arbitrarily given a value of 100) from six
independent transfection experiments performed in triplicate.
C shows that a single copy of the Pem promoter
element sequence containing the S1-, E1-, and E2-binding sites ( 81 nt
to 112 nt) suffices for transcription from a heterologous minimal
promoter ( c-fos). Shown are the average values (relative
to that from the empty vector ( c-fos), which was given an
arbitrary value of 1) from five independent transfection experiments
performed in triplicate.
|
|
Deletion analysis was then performed to define functionally important
cis elements in this 304-nt region. All deletion constructs tested had a common 3' end that included the transcription start sites
defined previously between 22 and 40 nt upstream of the exon 1-intron 1 junction (15). Deletion of sequences from nt 304 to 104 did not
appreciably reduce promoter activity (Fig. 2A). In contrast,
the 94 construct had much lower activity (about 10-fold less) than
the 104 construct, indicating that sequences between nt 104 and
94 were critical for maximal Pem Pd transcription. Even
less luciferase activity was detected from the 73 construct (60-fold
less than the 104 construct). We therefore conclude that the region
between nt 73 and 104 is indispensable for promoter activity.
Inspection of this 32-nt region revealed two putative Ets
protein-binding sites (E1 and E2 in Fig.
2B) and one Sp1 protein-binding site (S1 in Fig.
2B). To determine whether these putative binding sites were
necessary for Pem gene transcription, we mutated them and
tested for transcriptional activity. As shown in Fig. 2B, mutation of either the E1 or S1 site in the 112 Pem
construct strongly decreased promoter activity. Mutation of both sites
led to a further decrease in promoter activity, suggesting the
importance of both the Sp1 and the E1 Ets site for transcription.
Mutation of the other Ets site (E2) led to a less drastic but still
significant decrease in promoter activity (Fig. 2B).
Next we determined whether the region containing the Ets- and
Sp1-binding sites is sufficient to drive transcription. As shown in
Fig. 2C, a single copy of a sequence containing these three sites (nt 81 to 104) was sufficient to drive transcription from a
heterologous minimal c-fos promoter (4-6-fold over basal
level). This confirmed the functional importance of these Ets and Sp1 family binding sites, and thus we elected to call this region the
Pem Pd promoter element.
To determine the specificity of this Pem Pd promoter
element, we transfected the minimal 112 Pem construct
containing this element into the immature T cell lymphoma cell clones
SL12.1 and SL12.3, both of which express little or no Pem
transcripts from the endogenous Pem gene (Fig.
3A). We found that the SL12.1
cell clone expressed luciferase activity that was indistinguishable from background levels, and the SL12.3 cell clone expressed trace levels of luciferase activity that was much lower than that from the
SL12.4 cell clone (Fig. 3B).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
The Pem Pd element drives
transcription in a cell line-specific manner. A,
Northern blot analysis of total cellular RNA (10 µg) isolated from
the immature T cell lymphoma clones (SL12.1 and SL12.3) and a mature T
cell lymphoma clone (SL12.4). Similar loading and transfer of RNA were
shown by hybridization with a probe for cyclophilin. B, the
cell clones indicated were transiently transfected (1 µg) with the
112 Pem gene construct. Shown is the amount of
Renilla luciferase activity from the 112 construct
(±S.E.) relative to that from the empty vector (which was given an
arbitrary value of 1) after normalization of both against firefly
luciferase activity expressed from the internal control reporter
plasmid. The data are from two independent transfection experiments
performed in triplicate.
|
|
Identification of Proteins Interacting with the Pem Pd
Element--
Having shown that the Sp1 and Ets family binding sites
upstream of the Pem Pd transcription start site are
necessary for Pem Pd transcription, it was imperative to
identify the proteins interacting with these sites. Incubation of a
double-stranded 26-mer oligo probe containing this region with SL12.4
nuclear extracts and analysis by EMSA revealed at least four specific
protein-DNA complexes (Fig.
4A, complexes
1-4). An unlabeled oligo with a mutation in the Sp1-binding site
(oligo M1) competed for bands 3 and 4 but not bands 1 and 2, and thus
bands 1 and 2 represented proteins binding to the Sp1 site. Likewise,
an oligo with mutations in the Ets-binding site (M2) competed with
bands 1 and 2 only, indicating that complexes 3 and 4 contained
proteins binding to the Ets site. An oligo with both the Sp1 and Ets
(E1) sites (M3) had no effect on complex formation, demonstrating that
these two sites are responsible for the four complexes.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Sp1 and Ets family transcription factors bind
to the Pem Pd element. EMSA of SL12.4 nuclear
protein extracts (1 µg) incubated with a 32P-labeled
Pem Pd element probe (nt 81 to 104).
A, cold competition experiment in which a 50-fold molar
excess of unlabeled double-stranded oligos with mutations in the Sp1
site (M1), the Ets site (M2), or both sites
(M3) were added prior to incubation with hot probe. B, complex 1 and 2 correspond to Sp1 and
Sp3, respectively, as shown by supershift assay using anti-Sp1
(left panel) and anti-Sp3 (right panel)
monoclonal antibodies ( ). The arrows indicate the
relative migration of the relevant protein-DNA complexes with and
without antibody. C, complex 3 and 4 correspond to Elf1 and
Gabp, respectively, as shown by EMSAs performed by preincubating
nuclear proteins with rabbit polyclonal antisera against Elf1 and Gabp
( + ). The arrows indicate the relevant
complexes inhibited by antibody preincubation.
|
|
To identify specific proteins that bind to the Pem Pd
element, we used antibodies against Sp1 and Ets family members.
Monoclonal antibodies against Sp1 and Sp3 supershifted complexes 1 and
2, respectively (Fig. 4B), consistent with our mutant-oligo
competition experiments that demonstrated that complexes 1 and 2 contain proteins binding to the Sp1 family site in the Pem
Pd element (Fig. 4A). To identify the transcription
factors that bound to the Ets-binding site, we used a battery of
antibodies against different Ets family members. We found that
polyclonal antibodies against Elf1 and Gabp ( and ) inhibited the
generation of complexes 3 and 4, respectively (Fig. 4C). In
contrast, addition of monoclonal or polyclonal antibodies directed
against various other Ets family members, including Ets1, Ets2, Erg1,
and Elk1, failed to modify the nucleoprotein complexes formed with the
Pem Pd probe (data not shown). We conclude that the Ets
family members Elf1 and Gabp and the Sp1 family members Sp1 and Sp3
bind to the Pem Pd promoter element.
Transactivation of the Pem Pd by Sp1, Sp3, Elf1, and Gabp--
To
determine the functional importance of Sp1 and Ets family members in
Pem transcription, we performed a series of transient transfection experiments with the D. melanogaster
Schneider SL12 cell line, which lacks Sp1 family members (20, 21). As
shown in Fig. 5A, transfection
of increasing amounts of Sp1 expression plasmid (25-100 ng)
resulted in a concentration-dependent increase (5-20-fold)
in promoter activity. Similarly, Sp3 also transactivated the Pem
Pd in a dose-dependent manner. In fact, Sp3 was a more potent activator (20-800-fold) than Sp1. Sp1 and Sp3 together exerted
an additive effect in transactivating the Pem Pd (Fig. 5A). Elf1 and Gabp also stimulated luciferase activity in a
concentration-dependent manner (Fig. 5B).
Transfection of Elf1 and Gabp simultaneously resulted in an additive
increase in promoter activity (Fig 5B). Transfection of all
four transcription factor plasmids (Elf1, Gabp,
Sp1, and Sp3) also resulted in additive
stimulation of promoter activity.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Sp1, Sp3, Elf1, and Gabp transactivate
Pem Pd transcription. A and
B, Schneider cells cotransfected with the 112
Pem gene construct (0.5 µg) and the indicated amounts of
pPac-Sp1, pPac-Sp3, pPac-Elf1, and
pPac-Gabp ( and combined), or combinations of these.
Shown is the average luciferase activity, calculated as described for
Fig. 3B, from six independent transfection experiments
performed in triplicate, displayed in logarithmic scale
(left) or arithmetic scale (right).
|
|
To determine whether the three DNA-binding sites for these different
transcription factors was necessary for transactivation, we performed
cotransfection experiments with mutant Pem Pd constructs. In
these experiments, we used the Sp3 expression plasmid
rather than the Sp1 expression plasmid, as Sp3 had more
potent transactivation activity than Sp1. Results from cotransfection
of Sp3 expression plasmid with a Pem Pd construct
containing a mutation at the Sp1 site ( 112/S1) demonstrated that
transactivation by Sp3 required its cognate binding site (Fig.
6). Surprisingly, Sp3 transactivation also required the Ets-binding sites, as mutation of either the E1 or E2
sites prevented the induction of Pem Pd transcription in
response to Sp3 (Fig. 6). Thus it appeared that one or more Schneider
cell factors must bind to the Ets-binding sites for Sp3-mediated
transactivation to occur. Similarly, Elf1 and Gabp transactivation
required not only the Ets-binding sites but also the adjacent Sp1 site
(Fig. 6). This implies that Schneider cells express an endogenous Sp1
site-binding factor (although not an Sp1 family member) that
participates with mammalian Ets factors to drive Pem Pd
transcription. These results suggest that Ets and Sp1 family members
functionally cooperate to activate Pem Pd transcription (see
"Discussion").

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Transactivation of the Pem Pd
requires the Sp1/Sp3- and Ets-binding sites. Schneider cells
were cotransfected with 0.5 µg of either the wild-type 112
construct (WT) or versions of it that had mutations in the
Sp1 site (S1) or one of the two Ets sites (E1 and
E2) and 50 ng of pPac-Sp1, pPac-Sp3,
pPac-Elf1, or pPac-Gabp ( and ). Shown is
the average luciferase activity, calculated as described for Fig.
3B, from six independent transfection experiments performed
in triplicate.
|
|
To assess the functional importance of these transcription factors for
Pem transcription in mammalian cells, we transiently transfected plasmids encoding DN mutants into the SL12.4 T cell clone.
As shown in Fig. 7A,
transfection of DN-Gabp ( and ) expression plasmids
caused a dose-dependent repression of Pem Pd
promoter activity (Fig. 7A). A DN-Sp3 expression
plasmid also strongly inhibited Pem Pd transcriptional
activity in a dose-dependent manner (Fig. 7B).
Because the encoded DN-Sp3 protein lacks a transcription activation
domain but has a DNA-binding domain, it probably inhibits the activity
of all Sp1 family members, as they all have the same DNA binding
specificity (21). Thus, the inhibition by this DN protein shows that
one or more Sp1 family members are required for Pem
transcription in T cells. We conclude that the Ets factor Gabp and at
least one Sp1 family member are critical for Pem
transcription in SL12.4 cells.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Ets and Sp1 family members are essential for
Pem Pd transcription in SL12.4 T-lymphoma cells.
A and B, SL12.4 cells cotransfected with the
112 construct (1 µg) and the indicated amount of the
DN-Gabp and DN-Sp3 constructs. Shown is the
average luciferase activity, calculated as described for Fig.
3B, from six independent transfection experiments performed
in triplicate. C, Northern blot analysis of total cellular
RNA (10 µg) from untransfected SL12.4 cells (control) and
SL12.4 cells stably transfected with the DN-Sp3 expression
plasmid. Similar loading and transfer of RNA were verified by
hybridization with a probe for cyclophilin (cyclo).
|
|
Although these transient transfection experiments indicated the
importance of Sp1 and Ets family members for expression from our
minimal Pem Pd expression plasmid, they did not
address whether the endogenous Pem gene is similarly
regulated. To assess this point, we stably transfected SL12.4 cells
with the DN-Sp3 expression plasmid and examined mRNA
expression from the endogenous Pem gene in these cells. As
shown in Fig. 7C, stable transfection of DN-Sp3 decreased endogenous Pem mRNA levels, indicating that
the endogenous Pem promoter requires Sp3 and/or other Sp1
family members for activity.
Ets and Sp1 Transcription Factors Drive Aberrant Transcription of
the Pem Pd in Diverse Tumor Cell Types--
To determine whether the
cis- and trans-acting factors responsible for
Pem Pd transcription in the SL12.4 T-lymphoma cell clone
also regulate the expression of Pem in other tumor cell types, we examined Pem Pd regulation in five other tumor
cell lines. These cell lines exhibited a range of Pem Pd
promoter activity (Fig. 8A).
The neuroblastoma cell line N4TG1 and the prostate cancer cell line
PS-1 had a high level, which was from 150- to 200-fold above that of
the empty control vector. The ras-transformed fibroblast
cell line RAT-1 had promoter activity 30-fold above that of the control
vector. The B-myeloma cell lines S194/5 and M12 had comparatively low
promoter activity that were 5-6-fold above that of the empty control
vector.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 8.
Ets and Sp1 family members are required for
Pem Pd transcription in diverse tumor cells from
different tissues. A, tumor cell lines transfected with
1 µg of either the wild-type 112 construct (WT) or
versions of it that had mutations in the Sp1 site (S1) or
one of the two Ets sites (E1 and E2). Shown is
the average luciferase activity, calculated as described for Fig.
3B, from three independent transfection experiments
performed in triplicate. B, tumor cell lines cotransfected
with the Pem 112 construct (1 µg) and the indicated
amount of the DN-Sp3, DN-Gabp, or empty control
construct (2 µg). Shown is the average luciferase activity,
calculated as described for Fig. 3B, from three independent
transfection experiments performed in triplicate.
|
|
We found that four of the five tumor cell lines required all three
transcription factor-binding sites (S1, E1, and E2) in the Pem
Pd element for optimal transcription (Fig. 8A). The one exception was the M12 cell line, which appeared to only require the S1
and E2 sites, because it did not exhibit a statistically significant
(p > 0.05) decrease in luciferase activity when the E1
site was mutated. Transfection experiments with the DN-Gabp and DN-Sp3 plasmids showed that the Ets factor Gabp and one
or more Sp1 family members were necessary for maximal Pem
Pd transcription in all the tumor cell lines (Fig.
8B). We conclude that Pem Pd transcription in a wide range of tumor cell types depends on Ets and
Sp1 family members.
Ras Is Essential for Endogenous Pem Expression--
Because the
Ras signaling pathway is known to positively regulate Ets and
Sp1 family members (see "Discussion"), we examined the role of Ras
in Pem transcription. We found that transient transfection
of a DN-ras expression plasmid almost completely abrogated
Pem Pd transcriptional activity from the 112
Pem construct in SL12.4 cells, indicating that indeed Ras
does activate the Pem Pd (Fig.
9A). To determine whether Ras
also positively regulates Pem Pd transcription from the
endogenous Pem gene, we took two approaches. First, we
stably transfected SL12.4 cells with the DN-ras plasmid and
selected cell clones that expressed the plasmid. We found that
DN-ras-positive cell clones expressed lower levels of
endogenous Pem mRNA (up to ~3-foldless) than did
untransfected cells (Fig. 9B) or stably transfected cells
that expressed little or no DN-ras (data not shown). Second,
to determine whether Ras expression was sufficient to activate
endogenous Pem gene expression, we stably transfected an
activated Ha-ras expression plasmid into a
Pem-negative cell line, 10T1/2. We found that constitutively active Ha-ras strongly induced gene expression from the
endogenous Pem gene in 10T1/2 cells (Fig.
9B).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 9.
Pem Pd transcription requires the
Ras signaling pathway. A, SL12.4 cells
cotransfected with the 112 construct (1 µg) and DN-ras
(2 µg). Shown is the average luciferase activity, calculated as
described for Fig. 3B, from two independent transfection
experiments performed in triplicate. B, Northern blot
analysis of total cellular RNA (10 µg) from the cells shown.
Left panel, untransfected SL12.4 cells (control) and SL12.4
cells stably transfected with the DN-ras plasmid.
Transfected cells that expressed little or no DN-ras
mRNA expressed the same level of Pem mRNA as
untransfected cells (data not shown). Right panel,
untransfected 10T1/2 cells (control) and 10T1/2 cells stably
transfected with an activated Ha-ras expression plasmid.
10T1/2 cells stably transfected with empty vector lacked Pem
mRNA expression, just like the untransfected cells (data not
shown). Similar loading and transfer of RNA were verified by
hybridization with a probe for cyclophilin (cyclo).
|
|
Pem Transcription in Normal Granulosa Cells Requires the Pem Pd
Regulatory Element and Is Ras-dependent--
Last, we
determined whether non-malignant cells require the same regulatory
element for Pem transcription as do malignant cells. We
therefore investigated Pem Pd transcription in
primary ovarian granulosa cells, as mice granulosa cells normally
express Pem (22). As shown in Fig. 10,
we found that primary granulosa cells expressed high levels of
luciferase from the Pem 112 construct (almost 100-fold
over that from the empty vector). Mutation of Ets- and Sp1-binding
sites in the 112 construct drastically reduced luciferase expression,
suggesting that, like tumor cells, granulosa cells require these
binding sites for transcription. Cotransfection of the
DN-ras construct dramatically reduced expression. We
conclude that, like tumor cells, normal granulosa cells express the
Pem Pd in a ras-dependent
manner that involves Ets and Sp1 family members.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 10.
Pem Pd transcription in primary
granulosa cells requires Sp1/Sp3- and Ets-binding sites and the Ras
signaling pathway. Primary granulosa cells transfected with 1 µg
of either the wild-type 112 construct (WT) or versions of
it that had mutations in the Sp1 (S1) or Ets (E1)
sites. Also shown are granulosa cells cotransfected with the 112
construct (1 µg) and DN-ras (2 µg). Shown is the average
luciferase activity, calculated as described for Fig. 3B,
from two independent transfection experiments performed in
triplicate.
|
|
 |
DISCUSSION |
We have characterized a promoter transcriptionally active in
ovarian granulosa cells, placental trophoblast cells, and tumor cells
from a variety of lineages (see Figs. 1, 8, and 10 herein; see Ref.
15). We showed that this Pem Pd was
transcriptionally activated in response to the cell type-specific Ets
transcription factors Gabp and Elf1, as well as the ubiquitous zinc
finger transcription factors Sp1 and Sp3 (Figs. 4 and 5). Three closely
spaced binding sites for these factors between nt 80 and 104 were
sufficient for Pem Pd transcription (Figs. 2 and 6). We
found that Pem Pd transcription required the ras
pathway (Fig. 9), which is known to activate both Ets and Sp1 family
transcription factors and is constitutively activated in a large
proportion of tumors of different origins (23-26).
That Ets transcription factors are essential for Pem
transcription in diverse tumor cell types is consistent with the fact that many Ets family members play a role in tumor cell growth, invasion, and metastasis. For example, the founding member of the Ets
gene family, the v-ets retroviral gene, was originally identified as an oncogene based on its ability to transform cells (27,
28). Since then, at least 10 of the ~30 Ets domain-containing genes
have been shown to play a role in cancer, including ETS1, ETS2, FLI1,
TEL, ERG, and PSE (29). Our finding that Gabp was required for
Pem transcription in every tumor cell line tested (Figs.
7A and 8B) indicates that this Ets transcription
factor is also important in activating gene transcription in tumor
cells. However, whether Gabp is an oncogene that causes cancer remains to be determined.
Ets family members are also critical for the proper control of cellular
proliferation and differentiation of normal cells (30). There is a
wealth of knowledge about the role of Ets factors in some biological
systems, but less is known regarding their role in the female
reproductive tract, where Pem is expressed. In D. melanogaster, Elg, the fly orthologue of Gabp, is essential for
normal egg development, as null mutations in Elg cause tiny-egg syndrome (31). In mammals, Gabp positively regulates the expression of
the FBP gene in placenta (32), and thus this Ets factor may be important for normal placental development and function. Part of the
function of Gabp in placenta may be to allow Pem expression, as we
showed previously (5, 15) that Pem is strongly expressed in this
tissue, and we demonstrated here that Gabp positively regulated
Pem transcription in D. melanogaster Schneider
cells and several mammalian cell lines (Figs. 6-8). Gabp may also
positively regulate Pem expression in ovarian granulosa cells, as Pem
is expressed in ovarian granulosa cells in vivo (10, 22),
and we found that its expression in these cells depends on the presence of an Ets factor-binding site (Fig. 10).
Our demonstration that Sp1 family members are essential for
Pem transcription is not surprising given the fact that this
set of transcription factors participates in the regulation of a wide variety of genes expressed in both normal and malignant cells (33-36).
Sp1-regulated genes include those expressed in granulosa and
trophoblast cells, the type of cells that normally express Pem (32,
37). Sp1 is at a wide range of levels in different tissues (35, 38),
which could partly explain the unique expression pattern of Pem in
different tissues. For example, the high expression of Sp1 in normal
trophoblasts (38) and some types of tumor cells (38, 39) could, in
part, explain the high expression of Pem in these cell types (5,
10).
Surprisingly, we found that Sp1 was a less potent activator of
Pem than was the related family member Sp3 (Fig.
5A). This response contrasts with most other genes, which
are more strongly transcriptionally activated in response to Sp1 than
to Sp3 (40-42). In fact, rather than acting as an activator, Sp3
functions as a repressor for most gene promoters, including many that
are activated by Sp1 (21, 43-47). In contrast, we found that Sp3 had
an additive effect on Sp1-mediated transactivation of the
Pem Pd. We speculate that Sp3 is a potent
transcriptional activator of Pem because the Pem
Pd regulatory element possesses only a single Sp1 family binding
site (Fig. 2B). This notion is based on studies conducted on
other gene promoters that demonstrated that a single Sp1 family binding
site supports Sp3-mediated transcriptional activation, whereas multiple
Sp1 family binding sites support Sp3-mediated repression (48, 49). This
differential response has been suggested to result from the inability
of a single Sp3 repressor domain to overcome the glutamine-rich
activating region of Sp3 (48, 50, 51). Another factor that can dictate
the transcriptional response to Sp3 is the type of cell in which it
acts. For example, Sp3 activates the CD11d gene in myeloid
cells but represses this same gene in B and T cells (21, 52-54).
However, cell type cannot be the only determinant governing positive
Pem Pd regulation by Sp3, as we found that the Pem
Pd was induced by Sp3 in a wide range of cell types, including
ones that engender negative regulation for other genes in response to
Sp3 (21, 36, 37, 55, 56). Thus, we believe that intrinsic features of
the Pem Pd, rather than cell type, dictates its strong
induction in response to Sp3.
Our data support the notion that the Pem Pd is regulated by
Ets and Sp1 family members acting in a cooperative manner. First, the
close proximity of their binding sites in the Pem Pd
regulatory element (Figs. 2B and 4A) suggests
that Ets and Sp1 family members physically interact. Second, both Ets
sites and the single Sp1 site were required for maximal Pem
transcription in several different cell types, including normal
granulosa cells and tumor cells from a variety of cell lineages (Figs.
6, 8, and 10). Third, any single mammalian Ets or Sp1 family member
transactivated the Pem Pd less well than a combination of
them (Fig. 5). An additive transcriptional response to Ets and Sp1
family members was observed in Schneider cells, which we believe is an
underestimate, because our results suggested that there are endogenous
D. melanogaster factors that bind to the Ets- and
Sp1-binding sites and therefore elevate transcription levels in
response to any single mammalian transcription factor (Fig. 6). That
Ets and Sp1 family members cooperate to activate Pem Pd
transcription is supported by several other studies showing that most
Ets family members cooperate with other transcription factors,
including Sp1 family members, to strengthen their transactivation potential (26). For example, the Ets factor Gabp has been shown to
cooperate with Sp1 to activate at least three genes, including the
FBP gene in placenta (32, 57, 58). Elf1 forms a complex with
Sp1 or Sp3 to activate the transcription of the MRG1 and stem cell
leukemia tal-1 genes (59, 60).
That Sp1 and Ets family members and Ras are ubiquitously
expressed in many tumor cell types may partly explain why
Pem is ubiquitously expressed in tumor cells. In addition,
we showed that more than one member of each family is capable of
triggering Pem transcription, thereby further increasing the
range of tumor cell types that could express Pem. For
example, some cell types that express low levels of Sp1 express high
levels of Sp3 (49), both of which we found activated the Pem
Pd (Fig. 5). Another probable reason for Pem expression
in a wide variety of tumor cells is that Ras, which we demonstrated is
required for Pem transcription (Fig. 9), is constitutively
activated in ~50% of human tumors as a result of mutation (23, 61).
Ras induces the phosphorylation and consequent activation of Ets family
members (23), and thus Ras may drive Pem expression
in tumor cells as result of its ability to stimulate the activity of
Ets transcription factors. Consistent with this notion, Pem
is widely expressed in T cell tumors, but it is not expressed in normal
T cells (5), perhaps because the Ets factor Elf1, which is present in
both normal and malignant T cells, is only constitutively activated
when T cells become transformed (62). Ras proteins have also been
reported to activate gene transcription via Sp1 family members (25,
63), which could be another mechanism by which Pem is
transcriptionally activated in response to the Ras pathway.
Why is Pem ubiquitously expressed in a wide variety of tumor
cells but in a cell type- and stage-specific manner in normal cells?
First, despite the ubiquitous expression of Sp1 and Sp3, they are known
to display complex and intricate interactions with other transcription
factors (35, 38, 58, 64) that may confine their ability to activate the
Pem Pd in normal cells and expand this ability in tumor
cells. Second, we found that only some members of the Ets family can
activate Pem transcription, and thus the normally restricted
expression pattern of individual Ets transcription factors will confine
Pem expression to certain cell types. Third, and perhaps
most importantly, we speculate that even if a cell contains a
particular Ets factor required for Pem transcription, in
most cases the Ets factor will not be phosphorylated and hence will not
be capable of activating Pem transcription. This follows
from the fact that extracellular stimuli that activate Ras and
downstream mitogen-activated protein kinase pathways are known to cause
the phosphorylation of many Ets factors, an event that appears to be
necessary for Ets factors to regulate the transcription of specific
target genes (65, 66). Consistent with this notion, Pem is
weakly expressed in quiescent liver macrophages but is dramatically
induced when these cells are treated with lipopolysaccharide, a known
activator of Ras and mitogen-activated protein kinase pathways
in macrophages (22, 53). Quiescent macrophages constitutively express
all the transcription factors known to activate Pem
transcription (Elf1, Gabp, Sp1, and Sp3) (46, 47, 54, 67, 68), and thus
the induction of Pem in these cells probably results from
the activation of one or more of these factors by phosphorylation
rather than an induction in their levels.
Our discovery that the Pem homeobox gene is regulated by a
tissue- and stage-specific promoter that is aberrantly expressed in
tumors raises several questions. First, what are the signaling pathways
that normally trigger Pem transcription in response to Ets
and Sp1 family factors? The Ets factor Gabp is known to be activated by
the c-Jun N-terminal kinase and extracellular signal-regulated kinase
mitogen-activated protein kinase pathways (69, 70), and thus it will be
of interest to determine whether these pathways signal Pem
transcription in normal granulosa and trophoblast cells. Second, what
receptor-ligand interactions trigger Pem transcription in
normal cells? Virtually nothing is known about either the receptors or
ligands that activate Ets transcription factors in the female reproductive cells that express Pem. Third, what is the
precise mechanism by which tumor cells bypass the normal regulatory
constraints of Pem to constitutively express this homeobox
transcription factor? A full understanding of the regulatory networks
that control the Pem homeobox gene promoter that we have
defined in this report may be useful toward elucidating the
transcriptional perturbations that occur when normal cells become malignant.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Immunology,
Box 180, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-794-5526; Fax: 713-745-0846; E-mail: mwilkins@mdanderson.org.
Published, JBC Papers in Press, May 1, 2002, DOI 10.1074/jbc.M203374200
 |
ABBREVIATIONS |
The abbreviations used are:
nt, nucleotide;
oligo, oligonucleotide;
RPA, ribonuclease protection analysis;
EMSA, electrophoretic mobility shift assay;
DN, dominant negative.
 |
REFERENCES |
| 1.
|
Ford, H. L.
(1998)
Cell Biol. Int.
22,
397-400[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Caldas, C.,
and Aparicio, S.
(1999)
Cancer Metastasis Rev.
18,
313-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Castronovo, V.,
Kusaka, M.,
Chariot, A.,
Gielen, J.,
and Sobel, M.
(1994)
Biochem. Pharmacol.
47,
137-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sasaki, A. W.,
Doskow, J.,
MacLeod, C. L.,
Rogers, M. B.,
Gudas, L. J.,
and Wilkinson, M.
(1991)
Mech. Dev.
34,
155-164[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Wilkinson, M. F.,
Kleeman, J.,
Richards, J.,
and MacLeod, C. L.
(1990)
Dev. Biol.
141,
451-455[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Maiti, S.,
Meistrich, M. L.,
Wilson, G.,
Shetty, G.,
Marcelli, M.,
McPhaul, M. J.,
Morris, P. L.,
and Wilkinson, M. F.
(2001)
Endocrinology
142,
1567-1577[Abstract/Free Full Text]
|
| 7.
|
Rao, M.,
and Wilkinson, M. F.
(2002)
in
The Epididymis: From Molecules to Clinical Practice
(Robaire, B.
, and Hinton, B. T., eds)
, pp. 269-283, Plenum Publishing Corp., New York
|
| 8.
|
Sutton, K. A.,
and Wilkinson, M. F.
(1997)
Genomics
45,
447-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Fan, Y.,
Melhem, M. F.,
and Chaillet, J. R.
(1999)
Dev. Biol.
210,
481-496[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Lin, T. P.,
Labosky, P. A.,
Grabel, L. B.,
Kozak, C. A.,
Pitman, J. L.,
Kleeman, J.,
and MacLeod, C. L.
(1994)
Dev. Biol.
166,
170-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Lindsey, J. S.,
and Wilkinson, M. F.
(1996)
Dev. Biol.
179,
471-484[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Lindsey, J. S.,
and Wilkinson, M. F.
(1996)
Biol. Reprod.
55,
975-983[Abstract]
|
| 13.
|
Lemmens, I. H.,
Forsberg, L.,
Pannett, A. A.,
Meyen, E.,
Piehl, F.,
Turner, J. J.,
Van de Ven, W. J.,
Thakker, R. V.,
Larsson, C.,
and Kas, K.
(2001)
Biochem. Biophys. Res. Commun.
286,
426-431[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ono, T.,
Sato, S.,
Kimura, N.,
Tanaka, M.,
Shibuya, A.,
Old, L. J.,
and Nakayama, E.
(2000)
Int. J. Cancer
88,
845-851[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Maiti, S.,
Doskow, J., Li, S.,
Nhim, R. P.,
Lindsey, J. S.,
and Wilkinson, M. F.
(1996)
J. Biol. Chem.
271,
17536-17546[Abstract/Free Full Text]
|
| 16.
|
Brown, T. A.,
and McKnight, S. L.
(1992)
Genes Dev.
6,
2502-2512[Abstract/Free Full Text]
|
| 17.
|
Morris, J. K.,
and Richards, J. S.
(1996)
J. Biol. Chem.
271,
16633-16643[Abstract/Free Full Text]
|
| 18.
|
Chen, C. A.,
and Okayama, H.
(1988)
BioTechniques
6,
632-638[Medline]
[Order article via Infotrieve]
|
| 19.
|
Danielson, P. E.,
Forss-Petter, S.,
Brow, M. A.,
Calavetta, L.,
Douglass, J.,
Milner, R. J.,
and Sutcliffe, J. G.
(1988)
DNA (New York)
7,
261-267[Medline]
[Order article via Infotrieve]
|
| 20.
|
Courey, A. J.,
and Tjian, R.
(1988)
Cell
55,
887-898[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Hagen, G.,
Muller, S.,
Beato, M.,
and Suske, G.
(1994)
EMBO J.
13,
3843-3851[Medline]
[Order article via Infotrieve]
|
| 22.
|
Pitman, J. L.,
Lin, T. P.,
Kleeman, J. E.,
Erickson, G. F.,
and MacLeod, C. L.
(1998)
Dev. Biol.
202,
196-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Galang, C. K.,
Der, C. J.,
and Hauser, C. A.
(1994)
Oncogene
9,
2913-2921[Medline]
[Order article via Infotrieve]
|
| 24.
|
Halfon, M. S.,
Carmena, A.,
Gisselbrecht, S.,
Sackerson, C. M.,
Jimenez, F.,
Baylies, M. K.,
and Michelson, A. M.
(2000)
Cell
103,
63-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Kivinen, L.,
Tsubari, M.,
Haapajarvi, T.,
Datto, M. B.,
Wang, X. F.,
and Laiho, M.
(1999)
Oncogene
18,
6252-6261[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Wasylyk, B.,
Hahn, S. L.,
and Giovane, A.
(1993)
Eur. J. Biochem.
211,
7-18[Medline]
[Order article via Infotrieve]
|
| 27.
|
Janknecht, R.,
and Nordheim, A.
(1993)
Biochim. Biophys. Acta
1155,
346-356[Medline]
[Order article via Infotrieve]
|
| 28.
|
Leprince, D.,
Gegonne, A.,
Coll, J.,
de Taisne, C.,
Schneeberger, A.,
Lagrou, C.,
and Stehelin, D.
(1983)
Nature
306,
395-397[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Dittmer, J.,
and Nordheim, A.
(1998)
Biochim. Biophys. Acta
1377,
F1-F11[Medline]
[Order article via Infotrieve]
|
| 30.
|
Sementchenko, V. I.,
and Watson, D. K.
(2000)
Oncogene
19,
6533-6548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Schulz, R. A.,
The, S. M.,
Hogue, D. A.,
Galewsky, S.,
and Guo, Q.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10076-10080[Abstract/Free Full Text]
|
| 32.
|
Sadasivan, E.,
Cedeno, M. M.,
and Rothenberg, S. P.
(1994)
J. Biol. Chem.
269,
4725-4735[Abstract/Free Full Text]
|
| 33.
|
Kumar, A. P.,
and Butler, A. P.
(1999)
Cancer Lett.
137,
159-165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Ping, D.,
Boekhoudt, G.,
Zhang, F.,
Morris, A.,
Philipsen, S.,
Warren, S. T.,
and Boss, J. M.
(2000)
J. Biol. Chem.
275,
1708-1714[Abstract/Free Full Text]
|
| 35.
|
Rieber, M.,
and Strasberg Rieber, M.
(1999)
Int. J. Cancer
83,
359-364[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Schanke, J. T.,
Durning, M.,
Johnson, K. J.,
Bennett, L. K.,
and Golos, T. G.
(1998)
Mol. Endocrinol.
12,
405-417[Abstract/Free Full Text]
|
| 37.
|
Alliston, T. N.,
Maiyar, A. C.,
Buse, P.,
Firestone, G. L.,
and Richards, J. S.
(1997)
Mol. Endocrinol.
11,
1934-1949[Abstract/Free Full Text]
|
| 38.
|
Saffer, J. D.,
Jackson, S. P.,
and Annarella, M. B.
(1991)
Mol. Cell. Biol.
11,
2189-2199[Abstract/Free Full Text]
|
| 39.
|
Zannetti, A.,
Del, V.,
Carriero, M. V.,
Fonti, R.,
Franco, P.,
Botti, G.,
D'Aiuto, G.,
Stroppelli, M. P.,
and Salvatore, M.
(2000)
Cancer Res.
60,
1546-1551[Abstract/Free Full Text]
|
| 40.
|
McEwen, D. G.,
and Ornitz, D. M.
(1998)
J. Biol. Chem.
273,
5349-5357[Abstract/Free Full Text]
|
| 41.
|
Ritchie, S.,
Boyd, F. M.,
Wong, J.,
and Bonham, K.
(2000)
J. Biol. Chem.
275,
847-854[Abstract/Free Full Text]
|
| 42.
|
Tone, M.,
Powell, M. J.,
Tone, Y.,
Thompson, S. A.,
and Waldmann, H.
(2000)
J. Immunol.
165,
286-291[Abstract/Free Full Text]
|
| 43.
|
Discher, D. J.,
Bishopric, N. H., Wu, X.,
Peterson, C. A.,
and Webster, K. A.
(1998)
J. Biol. Chem.
273,
26087-26093[Abstract/Free Full Text]
|
| 44.
|
Krikun, G.,
Schatz, F.,
Mackman, N.,
Guller, S.,
Demopoulos, R.,
and Lockwood, C. J.
(2000)
Mol. Endocrinol.
14,
393-400[Abstract/Free Full Text]
|
| 45.
|
Kwon, H. S.,
Kim, M. S.,
Edenberg, H. J.,
and Hur, M. W.
(1999)
J. Biol. Chem.
274,
20-28[Abstract/Free Full Text]
|
| 46.
|
Noti, J. D.,
Johnson, A. K.,
and Dillon, J. D.
(2000)
J. Biol. Chem.
275,
8959-8969[Abstract/Free Full Text]
|
| 47.
|
Tomaras, G. D.,
Foster, D. A.,
Burrer, C. M.,
and Taffet, S. M.
(1999)
J. Leukocyte Biol.
66,
183-193[Abstract]
|
| 48.
|
Majello, B., De,
Luca, P.,
and Lania, L.
(1997)
J. Biol. Chem.
272,
4021-4026[Abstract/Free Full Text]
|
| 49.
|
Rajakumar, R. A.,
Thamotharan, S.,
Menon, R. K.,
and Devaskar, S. U.
(1998)
J. Biol. Chem.
273,
27474-27483[Abstract/Free Full Text]
|
| 50.
|
Birnbaum, M. J.,
van Wijnen, A. J.,
Odgren, P. R.,
Last, T. J.,
Suske, G.,
Stein, G. S.,
and Stein, J. L.
(1995)
Biochemistry
34,
16503-16508[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Kennett, S. B.,
Udvadia, A. J.,
and Horowitz, J. M.
(1997)
Nucleic Acids Res.
25,
3110-3117[Abstract/Free Full Text]
|
| 52.
|
De Luca, P.,
Majello, B.,
and Lania, L.
(1996)
J. Biol. Chem.
271,
8533-8536[Abstract/Free Full Text]
|
| 53.
|
Rao, K. M.
(2001)
J. Leukocyte Biol.
69,
3-10[Abstract/Free Full Text]
|
| 54.
|
Noti, J. D.
(1997)
J. Biol. Chem.
272,
24038-24045[Abstract/Free Full Text]
|
| 55.
|
Hagen, G.,
Dennig, J.,
Preiss, A.,
Beato, M.,
and Suske, G.
(1995)
J. Biol. Chem.
270,
24989-24994[Abstract/Free Full Text]
|
| 56.
|
Majello, B., De,
Luca, P.,
Hagen, G.,
Suske, G.,
and Lania, L.
(1994)
Nucleic Acids Res.
22,
4914-4921[Abstract/Free Full Text]
|
| 57.
|
Rosmarin, A. G.,
Luo, M.,
Caprio, D. G.,
Shang, J.,
and Simkevich, C. P.
(1998)
J. Biol. Chem.
273,
13097-13103[Abstract/Free Full Text]
|
| 58.
|
Shirasaki, F.,
Makhluf, H. A.,
LeRoy, C.,
Watson, D. K.,
and Trojanowska, M.
(1999)
Oncogene
18,
7755-7764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Bockamp, E. O.,
Fordham, J. L.,
Gottgens, B.,
Murrell, A. M.,
Sanchez, M. J.,
and Green, A. R.
(1998)
J. Biol. Chem.
273,
29032-29042[Abstract/Free Full Text]
|
| 60.
|
Han, B.,
Liu, N.,
Yang, X.,
Sun, H. B.,
and Yang, Y. C.
(2001)
J. Biol. Chem.
276,
7937-7942[Abstract/Free Full Text]
|
| 61.
|
Zachos, G.,
and Spandidos, D. A.
(1997)
Crit. Rev. Oncol. Hematol.
26,
65-75[Medline]
[Order article via Infotrieve]
|
| 62.
|
Bassuk, A. G.,
Barton, K. P.,
Anandappa, R. T., Lu, M. M.,
and Leiden, J. M.
(1998)
Mol. Med.
4,
392-401[Medline]
[Order article via Infotrieve]
|
| 63.
|
Spencer, J. A.,
and Misra, R. P.
(1999)
Oncogene
18,
7319-7327[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Tajima, A.,
Miyamoto, Y.,
Kadowaki, H.,
and Hayashi, M.
(2000)
Biochim. Biophys. Acta
1492,
377-384[Medline]
[Order article via Infotrieve]
|
| 65.
|
Yordy, J. S.,
and Muise-Helmericks, R. C.
(2000)
Oncogene
19,
6503-6513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Wasylyk, B.,
Hagman, J.,
and Gutierrez-Hartmann, A.
(1998)
Trends Biochem. Sci.
23,
213-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Serio, K. J.,
Hodulik, C. R.,
and Bigby, T. D.
(2000)
Am. J. Respir. Cell Mol. Biol.
23,
234-240[Abstract/Free Full Text]
|
| 68.
|
Tsai, E. Y.,
Falvo, J. V.,
Tsytsykova, A. V.,
Barczak, A. K.,
Reimold, A. M.,
Glimcher, L. H.,
Fenton, M. J.,
Gordon, D. C.,
Dunn, I. F.,
and Goldfeld, A. E.
(2000)
Mol. Cell. Biol.
20,
6084-6094[Abstract/Free Full Text]
|
| 69.
|
Avots, A.,
Hoffmeyer, A.,
Flory, E.,
Cimanis, A.,
Rapp, U. R.,
and Serfling, E.
(1997)
Mol. Cell. Biol.
17,
4381-4389[Abstract]
|
| 70.
|
Hoffmeyer, A.,
Avots, A.,
Flory, E.,
Weber, C. K.,
Serfling, E.,
and Rapp, U. R.
(1998)
J. Biol. Chem.
273,
10112-10119[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Xu and M. Komatsu
Promoter Cloning and Characterization of the Anti-vascular Proliferation Gene, R-ras: ROLE OF ETS- AND SP-BINDING MOTIFS
J. Biol. Chem.,
January 30, 2009;
284(5):
2706 - 2718.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. MacLean II, M. K. Rao, K. M.H. Doyle, J. S. Richards, and M. F. Wilkinson
Regulation of the Rhox5 Homeobox Gene in Primary Granulosa Cells: Preovulatory Expression and Dependence on SP1/SP3 and GABP
Biol Reprod,
December 1, 2005;
73(6):
1126 - 1134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Poch, N. S. Cutler, G. S. Yost, and R. N. Hines
MOLECULAR MECHANISMS REGULATING HUMAN CYP4B1 LUNG-SELECTIVE EXPRESSION
Drug Metab. Dispos.,
August 1, 2005;
33(8):
1174 - 1184.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|